Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.

Abstract

Exenatide twice-daily treatment was associated with a lower risk of CVD events and hospitalizations than treatment with other glucose-lowering therapies.

Full Text

• DOI - (DOI)
• ProQuest Information and Learning - full-text online
• Ovid Technologies, Inc. - full-text online
• HighWire Press - full-text online
• EBSCO - full-text online

Subjects

• Adult
• Cardiovascular Diseases
• Diabetes Mellitus, Type 2
• Drug Administration Schedule
• Female
• Humans
• Hypoglycemic Agents
• Male
• Middle Aged
• Peptides
• Receptors, Glucagon
• Retrospective Studies
• Venoms

Similar articles

• A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. (2007-01-08)
• Once weekly exenatide: efficacy, tolerability and place in therapy. (2013-02-20)
• Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. (2012-10-14)
• An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes. (2013-03-08)
• Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. (2012-09-29)
• Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. (2013-04-26)
• Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. (2005-10-18)
• The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. (2007-04-03)
• Exenatide extended-release: a review of its use in type 2 diabetes mellitus. (2012-08-07)

Authors

• Jennie H Best
• Byron J Hoogwerf
• William H Herman
• Elise M Pelletier
• Daniel B Smith
• Made Wenten
• Mohamed A Hussein

Publication date

2011-01-03

Journal

Journal topics

• Diabetes Mellitus

Language

Eng.

Copyright

Amylin Pharmaceuticals, San Diego, California, USA. jennie.best [at] amylin.com

Release reference

Diabetes Care. 2011 Jan;34(1):90-5

Related books

• Books of Cardiovascular Diseases
• Books of Diabetes Mellitus
• Books of Diabetes Mellitus, Type 2
• Books of Drug Administration Schedule
• Books of Hypoglycemic Agents
• Books of Peptides
• Books of Receptors, Glucagon
• Books of Retrospective Studies
• Books of Venoms